After the ECHO trial – Expanding access and choice through integrated services

Since the early 1990s, the evidence has been inconclusive as to whether using hormonal contraception increases women’s risk of acquiring HIV, particularly among progestogen-only injectable users. Observational studies indicated that women using progestogen-only injectable contraceptive methods may be at higher risk of acquiring human immunodeficiency virus (HIV). 

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial finds no link between HIV acquisition and the use of DMPA-IM, progestogen implant, and non-hormonal copper IUD. For more information please see the technical brief on the ECHO trial

Following the release of the result of the ECHO trial and the WHO latest guidance statement and revised Medical Eligibility Criteria (MEC) for contraceptive use, IPPF developed a follow-up technical brief to support IPPF MAs and frontline service providers’ work regarding the provision of the integrated contraceptive, HIV and other STI programmes to expand access and contraceptive choice. For more information, please see the attached technical brief After the ECHO trial – Expanding access and choice through integrated services, available in English and French.